04:17 PM EST, 02/19/2025 (MT Newswires) -- BioMarin Pharmaceutical ( BMRN ) late Wednesday reported Q4 non-GAAP earnings of $0.92 per diluted share, compared with $0.49 a year earlier.

Analysts polled by FactSet expected $0.74.

Revenue for the quarter ended Dec. 31 was $747.3 million, compared with $646.2 million a year earlier.

Analysts polled by FactSet expected $712.3 million.

For 2025, the company is projecting non-GAAP EPS of $4.20 to $4.40 on revenue of $3.1 billion to $3.2 billion. Analysts polled by FactSet are looking for $4.15 and $3.10 billion, respectively.

BioMarin shares recently were up 8.2% in Wednesday's after-hours session.

Price: 71.00, Change: +5.39, Percent Change: +8.22